In terms of Regulation 32(6) of SEBI LODR Regulations, enclosed herewith the Monitoring Agency Report issued by Care Ratings Limited for the quarter ended March 31, 2025
EMBDL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Embassy Developments Limited has filed the Monitoring Agency Report from CARE Ratings for the quarter ended March 31, 2025, covering the use of proceeds from its preferential issue of equity shares and convertible warrants worth ₹3,908.14 crore at ₹111.51 per share. During Q4FY25, the company received an additional ₹335 crore from warrant conversions, taking total proceeds received to ₹2,104.84 crore, of which ₹2,104.54 crore has been utilized across acquisitions (Embassy Residency, Embassy East Avenue, Embassy Eden, Blu Annex FSI rights, Sky Forest obligations), growth initiatives including the ₹455 crore acquisition of Squadron Developers from a related party (EREDSPL), and general corporate purposes. The balance ₹1,803.30 crore is pending and contingent on the conversion of 21.56 crore outstanding warrants. CARE Ratings confirmed no material deviation from stated objects, with all utilizations within the permitted ±10% range. The company's share price on May 15, 2025 stood at ₹101.85, which is below the warrant exercise price of ₹111.51, making remaining warrant conversions unlikely at current prices.
Routine compliance filing with no negative surprises; proceeds are being deployed as planned. However, the share price trading below the warrant exercise price (₹101.85 vs ₹111.51) is an unfavorable signal, as it raises doubts about the remaining ₹1,803.30 crore being realized through warrant conversions. The ₹100 crore Future Assets Advance extension also indicates slower-than-expected deployment of growth capital.